NDA 019884 · Baxter Hlthcare
Mesnex
Mesna · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 17, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 30, 1988
Approved uses
1
Original approval plus efficacy supplements
Registered trials
343
41 Phase 3, 44 recruiting
FAERS reports
8,485
8,228 serious, 1,763 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 10, 2025.
MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. MESNEX is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. ( 1 ) Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. ( 1 )
Mechanism: Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- MESNEX · MESNA 100MG/ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Mesna" as an intervention, any sponsor and status, largest first.
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002549 · 1,520 participants (planned) · Start Nov 1993
Drug: filgrastim; busulfan and 7 more · For: Leukemia
Sites: Innsbruck, Austria; Antwerp, Belgium; Bruges, Belgium · 75 sites in all
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00338377 · 1,230 participants · Start Feb 1, 2006 · Primary completion Feb 28, 2030
Drug: Dendritic Cell Immunization; Cyclophosphamide and 6 more · For: Melanoma
Sites: Houston, Texas
- SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated MyelomaPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002548 · 899 participants · Start Jan 1994 · Primary completion Oct 2003
Drug: recombinant interferon alfa; carmustine and 6 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Denver, Colorado; Tampa, Florida · 34 sites in all
- Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung CancerPivotal-lookingCompleted
European Lung Cancer Working PartyAcademic, hospital or other
NCT00622349 · 707 participants · Start Feb 2004 · Primary completion Mar 2009
Drug: Cisplatin, Ifosfamide, Gemcitabine; Ifosfamide, Gemcitabine and 1 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Brussels, Belgium; Lille, France; Athens, Greece · 4 sites in all
- Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal TumorPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00006734 · 587 participants · Start May 2001 · Primary completion Aug 2006
Drug: filgrastim; cyclophosphamide and 4 more · For: Sarcoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 239 sites in all
- Therapy Based on Stage of Disease and Risk Assessment in Treating Children With NeuroblastomaPivotal-lookingCompleted
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT00002802 · 500 participants (planned) · Start Jul 1990
Drug: carboplatin; cisplatin and 9 more · For: Neuroblastoma
Sites: Frechen, Germany
- R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell LymphomaPivotal-lookingCompleted
Lymphoma Study AssociationAcademic, hospital or other
NCT00137995 · 481 participants · Start Jun 2003 · Primary completion Oct 2008
Drug: Rituximab; Etoposide and 9 more · For: Lymphoma, Large-Cell, Diffuse
Sites: New York, New York; Sydney, Australia; Yvoir, Belgium · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia1,311
- pyrexia713
- off label use665
- neutropenia587
- anaemia411
- thrombocytopenia402
- vomiting387
- nausea381
- pancytopenia373
- sepsis367
- mucosal inflammation347
- diarrhoea346
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 147 |
| 2005 | 115 |
| 2006 | 119 |
| 2007 | 87 |
| 2008 | 139 |
| 2009 | 137 |
| 2010 | 190 |
| 2011 | 368 |
| 2012 | 338 |
| 2013 | 249 |
| 2014 | 244 |
| 2015 | 342 |
| 2016 | 337 |
| 2017 | 311 |
| 2018 | 567 |
| 2019 | 607 |
| 2020 | 640 |
| 2021 | 722 |
| 2022 | 623 |
| 2023 | 589 |
| 2024 | 655 |
| 2025 | 608 |
| 2026 | 351 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mesnex* (Mesna)
2024 spending
$690K
Beneficiaries
302
614 claims
Per beneficiary
$2,286
$76.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $596,229 |
| 2021 | $544,970 |
| 2022 | $659,475 |
| 2023 | $707,838 |
| 2024 | $690,420 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM, Smeland S, Bielack SS, et al. · Lancet Oncol 2016 · Clinical Trial, Phase III, Comparative Study
- Chemotherapy for meningiomas.
Kyritsis AP · J Neurooncol 1996 · Clinical Trial, Controlled Clinical Trial
- Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Rosen G, Forscher C, Lowenbraun S, et al. · Cancer 1994 · Clinical Trial
- The utility of the CADISS® system in laparoscopic cholecystectomy for acute cholecystitis.
Malvaux P, Gherardi D, Gryspeerdt F, et al. · Surg Endosc 2022 · Clinical Trial, Multicenter Study
- MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM, Doorduijn JK, Re A, et al. · Lancet Haematol 2021 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.